{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:41:45Z","timestamp":1780555305727,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2016\/03807-0"],"award-info":[{"award-number":["2016\/03807-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2017\/22927-0"],"award-info":[{"award-number":["2017\/22927-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2018\/04678-5"],"award-info":[{"award-number":["2018\/04678-5"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.bjid.2022.102717","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:45:15Z","timestamp":1668818715000},"page":"102717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Selection dynamics of HCV genotype 3 resistance-associated substitutions under direct-acting antiviral therapy pressure"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5785-1418","authenticated-orcid":false,"given":"Jo\u00e3o Paulo Vilela","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1118-8486","authenticated-orcid":false,"given":"Guilherme Rodrigues Fernandes","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2048-4589","authenticated-orcid":false,"given":"Cintia","family":"Bittar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana de Lourdes Candolo","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2420-4641","authenticated-orcid":false,"given":"Mar\u00edlia Silveira de Almeida","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo R\u00e9gis Leira","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2369-7686","authenticated-orcid":false,"given":"Fernanda Fernandes","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2022.102717_bib0001","unstructured":"World Health Organization (WHO). Hepatitis C. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c (accessed February 2022)."},{"key":"10.1016\/j.bjid.2022.102717_bib0002","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.bjid.2022.102717_bib0003","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade (MS). Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Hepatite C e Coinfec\u00e7\u00f5es. Bras\u00edlia: MS, 2019. http:\/\/www.aids.gov.br\/pt-br\/pub\/2017\/protocolo-clinico-e-diretrizes-terapeuticas-para-hepatite-c-e-coinfeccoes (accessed February 2022)."},{"key":"10.1016\/j.bjid.2022.102717_bib0004","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.bjid.2022.102717_bib0005","article-title":"HCV guidance: recommendations for testing, managing, and treating hepatitis C","year":"2019","journal-title":"Alexandria AASLD"},{"key":"10.1016\/j.bjid.2022.102717_bib0006","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.bjid.2022.102717_bib0007","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jhep.2016.08.021","article-title":"Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients","volume":"66","author":"Pol","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.bjid.2022.102717_bib0008","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jhep.2018.09.018","article-title":"Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir\/sofosbuvir in hepatitis C genotype 2 and 3","volume":"70","author":"Belperio","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.bjid.2022.102717_bib0009","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12876-020-01196-0","article-title":"Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study","volume":"20","author":"Charatcharoenwitthaya","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.bjid.2022.102717_bib0010","series-title":"Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Hepatite C e Coinfec\u00e7\u00f5es","year":"2015"},{"issue":"6B","key":"10.1016\/j.bjid.2022.102717_bib0011","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1016\/S0002-9343(99)00376-9","article-title":"Hepatitis C virus genotypes and quasispecies","volume":"107","author":"Davis","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.bjid.2022.102717_bib0012","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1128\/jvi.66.5.3225-3229.1992","article-title":"Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution","volume":"66","author":"Martell","year":"1992","journal-title":"J Virol"},{"key":"10.1016\/j.bjid.2022.102717_bib0013","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jhep.2004.12.013","article-title":"The origin of quasispecies: cause or consequence of chronic hepatitis C viral infection?","volume":"42","author":"Bowen","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.bjid.2022.102717_bib0014","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018","volume":"37","author":"Sorbo","year":"2018","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.bjid.2022.102717_bib0015","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3851\/IMP3237","article-title":"Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals","volume":"23","author":"Palanisamy","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bjid.2022.102717_bib0016","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jcv.2015.08.015","article-title":"Development and persistence of DAA resistance associated mutations in patients failing HCV treatment","volume":"72","author":"Paolucci","year":"2015","journal-title":"J Clin Virol"},{"key":"10.1016\/j.bjid.2022.102717_bib0017","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.bjid.2022.102717_bib0018","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3390\/v11020148","article-title":"Geographic distribution of HCV-GT3 subtypes and naturally occurring resistance associated substitutions","volume":"11","author":"Bagaglio","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.bjid.2022.102717_bib0019","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/apt.12646","article-title":"Review article: HCV genotype 3 \u2013 the new treatment challenge","volume":"39","author":"Ampuero","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bjid.2022.102717_bib0020","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.27095","article-title":"HCV Genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV","volume":"60","author":"Kanwal","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.bjid.2022.102717_bib0021","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12072-020-10019-z","article-title":"The effectiveness and safety of glecaprevir\/pibrentasvir in chronic hepatitis c patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study","volume":"14","author":"Nozaki","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.bjid.2022.102717_bib0022","series-title":"Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Hepatite C e Coinfec\u00e7\u00f5es","year":"2017"},{"key":"10.1016\/j.bjid.2022.102717_bib0023","series-title":"Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Hepatite C e Coinfec\u00e7\u00f5es","year":"2018"},{"key":"10.1016\/j.bjid.2022.102717_bib0024","doi-asserted-by":"crossref","first-page":"e62393","DOI":"10.1371\/journal.pone.0062393","article-title":"On hepatitis C virus evolution: the interaction between virus and host towards treatment outcome","volume":"8","author":"Bittar","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.bjid.2022.102717_bib0025","first-page":"95","article-title":"BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95\/98\/NT","volume":"41","author":"Hall","year":"1999","journal-title":"Nucl Acids Symp"},{"key":"10.1016\/j.bjid.2022.102717_bib0026","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1093\/nar\/22.22.4673","article-title":"CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice","volume":"22","author":"Thompson","year":"1994","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bjid.2022.102717_bib0027","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1053\/j.gastro.2015.07.043","article-title":"Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection","volume":"149","author":"Foster","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bjid.2022.102717_bib0028","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/jir.2017.0113","article-title":"Is interferon-based treatment of viral hepatitis c genotype 3 infection still of value in the era of direct-acting antivirals?","volume":"38","author":"Zar\u0119bska-Michaluk","year":"2018","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.bjid.2022.102717_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179764","article-title":"Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study","volume":"12","author":"Dalgard","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bjid.2022.102717_bib0030","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/hep.27567","article-title":"Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis","volume":"61","author":"Lawitz","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.bjid.2022.102717_bib0031","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/liv.13383","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme","volume":"37","author":"Hez\u00f3de","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.bjid.2022.102717_bib0032","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs","volume":"71","author":"Llaneras","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.bjid.2022.102717_bib0033","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/jvh.13218","article-title":"Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment","volume":"27","author":"Daniel","year":"2020","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.bjid.2022.102717_bib0034","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/MEG.0000000000001376","article-title":"Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan","volume":"31","author":"Sarwar","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.bjid.2022.102717_bib0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.coviro.2018.10.005","article-title":"Viral resistance in HCV infection","volume":"32","author":"Ceccherini-Silberstein","year":"2018","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.bjid.2022.102717_bib0036","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes","volume":"22","author":"Petruzziello","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bjid.2022.102717_bib0037","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4254\/wjh.v10.i9.543","article-title":"Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?","volume":"10","author":"Sharafi","year":"2018","journal-title":"World J Hepatol"},{"key":"10.1016\/j.bjid.2022.102717_bib0038","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL Recommendations on Treatment of Hepatitis C 2016","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.bjid.2022.102717_bib0039","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-8976-8_1","article-title":"Overview of direct-acting antiviral drugs and drug resistance of hepatitis c virus","volume":"1911","author":"Li","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.bjid.2022.102717_bib0040","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/hep.29693","article-title":"Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives","volume":"67","author":"Harrington","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.bjid.2022.102717_bib0041","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1099\/jgv.0.000932","article-title":"Manipulation of both virus- and cell-specific factors is required for robust transient replication of a hepatitis C virus genotype 3a sub-genomic replicon","volume":"98","author":"Kelly","year":"2017","journal-title":"J Gen Virol"},{"key":"10.1016\/j.bjid.2022.102717_bib0042","article-title":"A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir","volume":"102","author":"Campos","year":"2021","journal-title":"J Gen Virol"},{"key":"10.1016\/j.bjid.2022.102717_bib0043","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3851\/IMP3120","article-title":"Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin","volume":"22","author":"McPhee","year":"2017","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bjid.2022.102717_bib0044","series-title":"Accelerating access to hepatitis C diagnostics and treatment. Overcoming barriers in low- and middle-income countries. Global progress report 2020","year":"2021"},{"key":"10.1016\/j.bjid.2022.102717_bib0045","first-page":"e01249","article-title":"Pooled resistance analysis in patients with hepatitis c virus genotype 1 to 6 infection treated with glecaprevir-pibrentasvir in phase 2 and 3 clinical trials","volume":"62","author":"Krishnan","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2022.102717_bib0046","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2022.102717_bib0047","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","article-title":"Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials","volume":"59","author":"Svarovskaia","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2022.102717_bib0048","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2017.11.007","article-title":"Patterns of resistance-associated substitutions in patients with chronic hcv infection following treatment with direct-acting antivirals","volume":"154","author":"Dietz","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bjid.2022.102717_bib0049","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/COH.0000000000000177","article-title":"Resistance to direct-acting antiviral agents: clinical utility and significance","volume":"10","author":"Cento","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.bjid.2022.102717_bib0050","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","article-title":"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir","volume":"61","author":"Donaldson","year":"2015","journal-title":"Hepatology"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S141386702200410X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S141386702200410X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:32:31Z","timestamp":1778812351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S141386702200410X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S141386702200410X"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2022.102717","relation":{},"ISSN":["1413-8670"],"issn-type":[{"value":"1413-8670","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selection dynamics of HCV genotype 3 resistance-associated substitutions under direct-acting antiviral therapy pressure","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2022.102717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedade Brasileira de Infectologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102717"}}